In an in-silico study by Akın-Balı et al., 6 to 8 new mutations in the Nrf2-Keap1 signaling pathway were identified, indicating a disruption of the Nrf2 inhibitory pathway and activation of this factor in patients with ALL. The gene discussed is NFE2L2; the disease is acute lymphoblastic leukemia.